CERA

Close Menu

Donate

Donate to CERA

Subscribe

Get monthly updates

Clinical trials

Take part in research
Close Close

Science and Research

Gene Therapy Study to Evaluate the Safety and Efficacy of GT005 in people with Geographic Atrophy Secondary to Age-Related Macular Degeneration

This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.

Overview

This Phase II clinical study is exploring the safety and efficacy of two doses of GT005 administered as a single subretinal injection in people with geographic atrophy secondary to age-related macular degeneration.

Participants are randomised into either a treated or no treatment/control group and will be followed up for 2 years.

  • Principal Investigator
Dr Thomas Edwards

Learn more

View this study at ClinicalTrials.gov

This database listing provides more detailed information about the EXPLORE study.

Read More

View this study at ClinicalTrials.gov

This database listing provides more detailed information about the HORIZON study.

Read More

Related Pages

News

Australia’s first investigational gene therapy trials for dry age-related macular degeneration under way

Australia’s first clinical trials of an investigational gene therapy to treat dry age-related macular degeneration (AMD) have begun at the Centre for Eye Research Australia (CERA).